

Francesco Grossi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1634903/francesco-grossi-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

292
papers

10,023
citations

44
h-index

92
g-index

385
ext. papers

13,136
ext. citations

4.6
avg, IF

6.05
L-index

#	Paper	IF	Citations
292	High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status.. <i>Journal of Hematology and Oncology</i> , 2022 , 15, 9	22.4	0
291	Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib.. <i>Clinical Pharmacology: Advances and Applications</i> , 2022 , 14, 1-9	1.5	
290	Survival benefit with adjuvant chemotherapy in stage III microsatellite-high/deficient mismatch repair colon cancer: a systematic review and meta-analysis.. <i>Scientific Reports</i> , 2022 , 12, 1055	4.9	0
289	First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.. <i>Lung Cancer</i> , 2022 , 167, 8-16	5.9	1
288	Radiation-Related Deregulation of TUBB3 and BRCA1/2 and Risk of Secondary Lung Cancer in Women With Breast Cancer. <i>Clinical Breast Cancer</i> , 2021 , 21, 218-230.e6	3	1
287	Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort Study. <i>Cancers</i> , 2021 , 13,	6.6	4
286	Nivolumab plus ipilimumab for the first-line treatment of metastatic NSCLC. <i>Expert Review of Anticancer Therapy</i> , 2021 , 21, 705-713	3.5	2
285	Impact of BMI on Survival Outcomes of Immunotherapy in Solid Tumors: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	6
284	The Appropriateness of Invasive Ventilation in COVID-19 Positive Cancer Patients: Proposal of a New Prognostic Score. <i>Viruses</i> , 2021 , 13,	6.2	1
283	Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy 2021 , 9,		20
282	Metronomic oral vinorelbine in previously untreated advanced non-small-cell lung cancer patients unfit for platinum-based chemotherapy: results of the randomized phase II Tempo Lung trial. <i>ESMO Open</i> , 2021 , 6, 100051	6	4
281	The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥50% advanced non-small-cell lung cancer. <i>ESMO Open</i> , 2021 , 6, 100078	6	17
280	Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review. <i>Cancers</i> , 2021 , 13,	6.6	12
279	Immune checkpoint inhibitors for treatment of small-cell lung cancer: a systematic review and meta-analysis. <i>Annals of Translational Medicine</i> , 2021 , 9, 705	3.2	3
278	Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	11
277	Adjuvant pembrolizumab for melanoma: update from the EORTC 1325-MG/KEYNOTE-054 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 573-575	21.7	3
276	INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2) 2021 , 9,		3

275	Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors. <i>Pharmaceutics</i> , 2021 , 13,	6.4	10
274	Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time?. <i>American Journal of Clinical Dermatology</i> , 2021 , 22, 511-522	7.1	1
273	Metabolic Interplay between the Immune System and Melanoma Cells: Therapeutic Implications. <i>Biomedicines</i> , 2021 , 9,	4.8	3
272	Post-progression outcomes of NSCLC patients with PD-L1 expression $\geq 50\%$ receiving first-line single-agent pembrolizumab in a large multicentre real-world study. <i>European Journal of Cancer</i> , 2021 , 148, 24-35	7.5	8
271	Management of patients with cancer during the COVID-19 pandemic: The Italian perspective on the second wave. <i>European Journal of Cancer</i> , 2021 , 148, 112-116	7.5	3
270	Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. <i>European Journal of Cancer</i> , 2021 , 150, 224-231	7.5	8
269	PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. <i>Journal of Translational Medicine</i> , 2021 , 19, 270	8.5	3
268	The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab. <i>Cancers</i> , 2021 , 13,	6.6	5
267	Triage process for the assessment of coronavirus disease 2019-positive patients with cancer: The ONCOVID prospective study. <i>Cancer</i> , 2021 , 127, 1091-1101	6.4	4
266	Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03). <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211022905	5.4	0
265	First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2021 , 397, 375-386	4.0	209
264	A case of sudden brain metastases progression after temporary targeted therapy discontinuation: when to regret a drug holiday. <i>Melanoma Research</i> , 2021 , 31, 190-193	3.3	0
263	Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study. <i>Thoracic Cancer</i> , 2021 , 12, 880-889	3.2	13
262	COVID-19 vaccination mimicking lymph-node progression in a patient with melanoma: a case report. <i>Melanoma Research</i> , 2021 , 31, 490-493	3.3	0
261	Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 1	7.4	1
260	Serum levels of VCAM-1 are associated with survival in patients treated with nivolumab for NSCLC. <i>European Journal of Clinical Investigation</i> , 2021 , e13668	4.6	1
259	Current state of the art and future perspectives with immunotherapy in the management of small cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2021 , 15, 1427-1435	3.8	3
258	Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 1438-1447	21.7	18

257	Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 $\geq 50\%$ metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy.. <i>Thoracic Cancer</i> , 2021 ,	3.2	2
256	1900P RAMES trial: A multicentre, double-blind, randomized, phase II study on gemcitabine plus ramucirumab versus gemcitabine alone as second-line treatment for advanced malignant pleural mesothelioma (MPM). <i>Annals of Oncology</i> , 2020 , 31, S1078	10.3	2
255	1689P The appropriateness of invasive ventilation in COVID-19 positive cancer patients: The hardest decision for oncologists. <i>Annals of Oncology</i> , 2020 , 31, S998-S999	10.3	78
254	1696P Incidence of influenza-like illness (ILI) in cancer patients during COVID-19: The ONCOVID prospective observational study. <i>Annals of Oncology</i> , 2020 , 31, S1001	10.3	78
253	1705P SARS-CoV-2 infection among cancer patients receiving antitumor treatment in Italy: A nationwide observational study (CIPOMO ONCO COVID-19). <i>Annals of Oncology</i> , 2020 , 31, S1004-S1005	10.3	78
252	Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non-small Cell Lung Cancer in the Italian National Health Service. <i>Clinical Therapeutics</i> , 2020 , 42, 830-847	3.5	5
251	Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50 . <i>Cancer Immunology, Immunotherapy</i> , 2020 , 69, 2209-2221	7.4	32
250	Developing a risk assessment score for patients with cancer during the coronavirus disease 2019 pandemic. <i>European Journal of Cancer</i> , 2020 , 135, 47-50	7.5	15
249	COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. <i>Lancet Oncology</i> , 2020 , 21, 914-922	21.7	328
248	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression $\geq 50\%$ and Their Relationship With Clinical Outcomes. <i>Clinical Lung Cancer</i> , 2020 , 21, 498-508.e2	4.9	27
247	Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1505-1517	2.2	298
246	Pharmacotherapeutic advances with anaplastic lymphoma kinase inhibitors for the treatment of non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 931-940	4	4
245	Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2020 , 11, 125	8.4	22
244	Association of Steroids use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2020 , 12,	6.6	73
243	Coronavirus infection and immune system: An insight of COVID-19 in cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 153, 103059	7	18
242	Immune related adverse events and response to immunotherapy: Focus on corticosteroids. <i>Lung Cancer</i> , 2020 , 145, 225	5.9	3
241	PTEN Expression as a Complementary Biomarker for Mismatch Repair Testing in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	15
240	Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment. <i>Clinical and Translational Oncology</i> , 2020 , 22, 1603-1610	3.6	2

239	Strategies for Increasing the Effectiveness of Aromatase Inhibitors in Locally Advanced Breast Cancer: An Evidence-Based Review on Current Options. <i>Cancer Management and Research</i> , 2020 , 12, 675-686	3.6	14
238	PCSK9 is a promising prognostic marker in patients with advanced NSCLC. <i>Cancer Immunology, Immunotherapy</i> , 2020 , 69, 491-492	7.4	5
237	Reorganisation of medical oncology departments during the novel coronavirus disease-19 pandemic: a nationwide Italian survey. <i>European Journal of Cancer</i> , 2020 , 132, 17-23	7.5	62
236	Impact of Use of Gastric-Acid Suppressants and Oral Anti-Cancer Agents on Survival Outcomes: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2020 , 12,	6.6	10
235	Practical review for diagnosis and clinical management of perihilar cholangiocarcinoma. <i>World Journal of Gastroenterology</i> , 2020 , 26, 3542-3561	5.6	10
234	Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives. <i>Expert Review of Respiratory Medicine</i> , 2020 , 14, 367-383	3.8	11
233	Comparison Between F-FDG PET-Based and CT-Based Criteria in Non-Small Cell Lung Cancer Patients Treated with Nivolumab. <i>Journal of Nuclear Medicine</i> , 2020 , 61, 990-998	8.9	30
232	Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study. <i>Cancers</i> , 2020 , 12,	6.6	11
231	Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression $\geq 50\%$: a multicenter study with external validation 2020 , 8,		29
230	Novel treatment strategies for early-stage lung cancer: the oncologist's perspective. <i>Journal of Thoracic Disease</i> , 2020 , 12, 3390-3398	2.6	10
229	LBA1 First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743. <i>Annals of Oncology</i> , 2020 , 31, S1441	10.3	4
228	Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920968463	5.4	7
227	Letter of response to comments on: Developing a risk assessment score for patients with cancer during COVID-19 pandemic: A war on two fronts. <i>European Journal of Cancer</i> , 2020 , 140, 161-162	7.5	1
226	IDH Signalling Pathway in Cholangiocarcinoma: From Biological Rationale to Therapeutic Targeting. <i>Cancers</i> , 2020 , 12,	6.6	8
225	Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare Histological Subtypes (CHANCE trial). <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920968463	5.4	983 ²
224	A Review of Clinical Practice Guidelines and Treatment Recommendations for Cancer Care in the COVID-19 Pandemic. <i>Cancers</i> , 2020 , 12,	6.6	11
223	Crizotinib in -Deregulated or -Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial. <i>Clinical Cancer Research</i> , 2019 , 25, 7312-7319	12.9	80
222	Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	17

221	Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab. <i>Cancers</i> , 2019 , 11,	6.6	4
220	PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells. <i>Frontiers in Immunology</i> , 2019 , 10, 1248-4	8.4	85
219	Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds. <i>Expert Opinion on Investigational Drugs</i> , 2019 , 28, 513-523	5.9	11
218	Identification and Management of Immune Checkpoint Inhibitor-Related Myocarditis: Use Troponin Wisely. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2201-2205	2.2	22
217	Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients. <i>Molecular Medicine</i> , 2019 , 25, 15	6.2	17
216	The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients. <i>Journal of Translational Medicine</i> , 2019 , 17, 74	8.5	41
215	Integrated Somatic and Germline Whole-Exome Sequencing Analysis in Women with Lung Cancer after a Previous Breast Cancer. <i>Cancers</i> , 2019 , 11,	6.6	1
214	Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression. <i>Clinical Lung Cancer</i> , 2019 , 20, 178-185.e2	4.9	23
213	Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus. <i>Immunotherapy</i> , 2019 , 11, 873-879	3.8	10
212	Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases. <i>Anticancer Research</i> , 2019 , 39, 4265-4271	2.3	19
211	Surgery or Locoregional Approaches for Hepatic Oligometastatic Pancreatic Cancer: Myth, Hope, or Reality?. <i>Cancers</i> , 2019 , 11,	6.6	16
210	Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer. <i>Clinical and Experimental Metastasis</i> , 2019 , 36, 449-456	4.7	8
209	Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial. <i>Lung Cancer</i> , 2019 , 134, 121-126	5.9	1
208	Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 1351-1358	7.4	12
207	Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	21
206	Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial. <i>Lung Cancer</i> , 2019 , 134, 210-217	5.9	8
205	Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer. <i>European Journal of Cancer</i> , 2019 , 123, 72-80	7.5	34
204	Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach. <i>PLoS ONE</i> , 2019 , 14, e0224027	3.7	4

203	Abstract CT043: Outcomes among patients (pts) with metastatic nonsquamous NSCLC with liver metastases or brain metastases treated with pembrolizumab (pembro) plus pemetrexed-platinum: Results from the KEYNOTE-189 study 2019 ,		8
202	Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges. <i>Cancers</i> , 2019 , 12,	6.6	49
201	Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population. <i>Oncologist</i> , 2019 , 24, e1165-e1171	5.7	23
200	Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer 2019 , 7, 316		56
199	Facies analysis in the Second Cycle Messinian evaporites predating the early Pliocene reflooding: the Balza Soletta section (Corvillo Basin, central Sicily). <i>Italian Journal of Geosciences</i> , 2019 , 138, 301-316 ¹⁻⁷		5
198	Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. <i>Lung Cancer</i> , 2019 , 129, 35-40	5.9	77
197	Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019 , 145, 479-485	4.9	174
196	Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018 , 378, 2078-2092	59.2	2820
195	Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy. <i>Lung Cancer</i> , 2018 , 117, 64-69	5.9	10
194	Potential cardiac risk of immune-checkpoint blockade as anticancer treatment: What we know, what we do not know, and what we can do to prevent adverse effects. <i>Medicinal Research Reviews</i> , 2018 , 38, 1447-1468	14.4	12
193	Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients. <i>Oncologist</i> , 2018 , 23, 936-942	5.7	46
192	NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer. <i>Oncologist</i> , 2018 , 23, 1133-e112	5.7	10
191	Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme. <i>European Journal of Cancer</i> , 2018 , 100, 126-134 ⁷⁻⁵		65
190	The record of the Messinian salinity crisis in mobile belts: Insights from the Molise allochthonous units (southern Apennines, Italy). <i>Palaeogeography, Palaeoclimatology, Palaeoecology</i> , 2018 , 503, 112-130 ⁹		5
189	NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology</i> , 2018 , 19, 799-811	21.7	44
188	Abstract CT075: KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC 2018 ,		5
187	Randomized phase II trial of oral vinorelbine (OV) and cisplatin (P) followed by maintenance with single-agent OV versus (vs) gemcitabine (GEM) and P followed by maintenance with single-agent GEM as first-line chemotherapy (CT) in locally advanced (LA) or metastatic non-small-cell lung cancer (NSCLC) patients (pts) with squamous (sq) histological type. <i>Journal of Clinical Oncology</i> , 2018 , 36, 835-843	2.2	
186	KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?. <i>Annals of Oncology</i> , 2018 , 29, viii529-viii530	10.3	2

185	P1.01-79 CheckMate 817: Safety of Flat-Dose Nivolumab Plus Weight-Based Ipilimumab for the First-line (1L) Treatment of Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2018 , 13, S493	8.9	5
184	Successful treatment of lung adenocarcinoma with gefitinib based on gene amplification. <i>Journal of Thoracic Disease</i> , 2018 , 10, E779-E783	2.6	1
183	Afatinib and Erlotinib in the treatment of squamous-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 2055-2062	4	18
182	Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy. <i>Current Clinical Pharmacology</i> , 2018 , 13, 76-84 ²⁻⁵		5
181	The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 1969-1976	4	16
180	Impact of low-dose computed tomography screening on lung cancer mortality among asbestos-exposed workers. <i>International Journal of Epidemiology</i> , 2018 , 47, 1981-1991	7.8	4
179	Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, e183486	13.4	16
178	Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1146-1155	8.9	57
177	30 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT). <i>ESMO Open</i> , 2018 , 3, e000298	6	7
176	CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine. <i>Expert Opinion on Biological Therapy</i> , 2018 , 18, 829-835	5.4	8
175	Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1281-1287	2.2	84
174	Circulating Tumor DNA Reflects Tumor Metabolism Rather Than Tumor Burden in Chemotherapy-Naive Patients with Advanced Non-Small Cell Lung Cancer: F-FDG PET/CT Study. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 1764-1769	8.9	33
173	Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy. <i>British Journal of Cancer</i> , 2017 , 116, 36-43	8.7	12
172	Understanding the checkpoint blockade in lung cancer immunotherapy. <i>Drug Discovery Today</i> , 2017 , 22, 1266-1273	8.8	36
171	P2.01-067 The Relevance of CEA and CYFRA21-1 as Predictive Factors in Nivolumab Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S827-S828	8.9	2
170	P3.02c-095 Italian Nivolumab Expanded Access Programme: Efficacy and Safety Data in Squamous Non-Small Cell Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S1336-S1337	8.9	2
169	Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 551-561	5.9	4
168	Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2017 , 16, 573-585	4.1	16

167	Exosomes: a new horizon in lung cancer. <i>Drug Discovery Today</i> , 2017 , 22, 927-936	8.8	64
166	Is the occurrence of a sigmoidal ventral border in <i>Cyprideis torosa</i> (Jones) valves linked to salinity? A morphometrical analysis approach. <i>Journal of Micropalaeontology</i> , 2017 , 36, 70-79	2	2
165	Efficacy and safety data from patients with advanced non-squamous NSCLC and brain metastases from the nivolumab expanded access programme (EAP) in Italy. <i>Annals of Oncology</i> , 2017 , 28, v469	10.3	3
164	New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 19-33	4	5
163	MA 10.06 Real-World Results in Non-Squamous Non-Small Cell Lung Cancer Patients: Italian Nivolumab Expanded Access Program. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S1841	8.9	2
162	Overall survival (OS) of selected patients (Pts) with non-small cell lung cancer (NSCLC) receiving nivolumab beyond progression. <i>Annals of Oncology</i> , 2017 , 28, vi61	10.3	2
161	Italian nivolumab expanded access programme: real-world results in non-squamous non-small cell lung cancer patients. <i>Annals of Oncology</i> , 2017 , 28, v410-v411	10.3	2
160	Il Costo Degli Eventi Avversi Associati ad Afatinib, Erlotinib e Gefitinib Nel Trattamento del Tumore del Polmone non a Piccole Cellule con Mutazione EGFR. <i>Global & Regional Health Technology Assessment</i> , 2017 , 4, grhta.5000270	0.2	1
159	Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	28
158	Reply to the Letter to the Editor by C. Nicolazzo et al.: "Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy". <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	1
157	Downregulation of miR-99a/let-7c/miR-125b miRNA cluster predicts clinical outcome in patients with unresected malignant pleural mesothelioma. <i>Oncotarget</i> , 2017 , 8, 68627-68640	3.3	19
156	Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC. <i>Lung Cancer</i> , 2016 , 100, 30-37	5.9	3
155	Vinflunine for the treatment of non-small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2016 , 25, 1447-1455	5.9	2
154	Efficacy and safety of nivolumab in elderly patients (pts) with advanced squamous non small cell lung cancer (Sq-NSCLC) participating in the expanded access programme (EAP) in Italy. <i>Annals of Oncology</i> , 2016 , 27, vi369	10.3	2
153	Performance comparison of two commercial human whole-exome capture systems on formalin-fixed paraffin-embedded lung adenocarcinoma samples. <i>BMC Cancer</i> , 2016 , 16, 692	4.8	23
152	Whole exome sequencing of independent lung adenocarcinoma, lung squamous cell carcinoma, and malignant peritoneal mesothelioma: A case report. <i>Medicine (United States)</i> , 2016 , 95, e5447	1.8	12
151	Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. <i>Annals of Oncology</i> , 2016 , 27, 417-23	10.3	101
150	Recent advances in squamous non-small cell lung cancer: evidence beyond predictive biomarkers. <i>Expert Review of Anticancer Therapy</i> , 2016 , 16, 1-4	3.5	5

149	Italian cohort of nivolumab Expanded Access Programme (EAP): Preliminary data from a real-world population.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3067-3067	2.2	4
148	Safety and efficacy of buparlisib (BKM120) and chemotherapy in advanced, squamous non-small cell lung cancer (sqNSCLC): Results from the phase Ib/II BASALT-2 and BASALT-3 studies.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e20522-e20522	2.2	5
147	Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2016 , 16, 1142-54	2.2	8
146	Italian multicenter phase III randomized study of cisplatin-etoposide with or without bevacizumab as first-line treatment in extensive stage small cell lung cancer (SCLC): GOIRC-AIFA FARM6PMFJM trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 8513-8513	2.2	
145	Screening with low-dose computed tomography (LDCT) of asbestos-exposed subjects and lung cancer (LC) mortality.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1554-1554	2.2	
144	Prognostic and Therapeutic Implications of MicroRNA in Malignant Pleural Mesothelioma. <i>MicroRNA (Sharjah, United Arab Emirates)</i> , 2016 , 5, 12-18	2.9	9
143	Hematopoietic growth factors in lung cancer. <i>Current Opinion in Oncology</i> , 2016 , 28, 135-44	4.2	4
142	Efficacy and safety data from patients with advanced squamous NSCLC and brain metastases participating in the nivolumab Expanded Access Programme (EAP) in Italy. <i>Annals of Oncology</i> , 2016 , 27, vi425	10.3	13
141	Oral vinorelbine plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of advanced non-squamous non-small-cell lung cancer: cost minimization analysis in 12 European countries. <i>Current Medical Research and Opinion</i> , 2016 , 32, 1577-84	2.5	4
140	Advances in treatment of mesothelioma. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 1197-205	4	11
139	CD133-Positive Cells from Non-Small Cell Lung Cancer Show Distinct Sensitivity to Cisplatin and Afatinib. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2015 , 63, 207-14	4	8
138	Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 665-72	8.9	22
137	Belagenpumatucel-L for the treatment of non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2015 , 15, 1371-9	5.4	8
136	Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 1319-1327	8.9	112
135	Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition. <i>Targeted Oncology</i> , 2015 , 10, 393-404	5	30
134	Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2015 , 10, e50-2	8.9	11
133	Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors. <i>International Journal of Cancer</i> , 2015 , 137, 2947-58	7.5	7
132	Next generation sequencing in non-small cell lung cancer: new avenues toward the personalized medicine. <i>Current Drug Targets</i> , 2015 , 16, 47-59	3	34

131	Next-Generation Sequencing Workflow for NSCLC Critical Samples Using a Targeted Sequencing Approach by Ion Torrent PGM Platform. <i>International Journal of Molecular Sciences</i> , 2015 , 16, 28765-82	6.3	29
130	Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I-III Non-Small Cell Lung Cancer. <i>Disease Markers</i> , 2015 , 2015, 302649	3.2	18
129	Afatinib for the treatment of non-small cell lung cancer. <i>Expert Opinion on Orphan Drugs</i> , 2015 , 3, 1357-1364	1	
128	Is <i>Cyprideis agrentina</i> Decima a good paleosalinometer for the Messinian Salinity Crisis? Morphometrical and geochemical analyses from the Eraclea Minoa section (Sicily). <i>Palaeogeography, Palaeoclimatology, Palaeoecology</i> , 2015 , 419, 75-89	2.9	19
127	Severe hypocalcemia and life-threatening ventricular arrhythmias: case report and proposal of a diagnostic and therapeutic algorithm. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2015 , 12, 265-8		7
126	Phase III trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma (MPM).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 7501-7501	2.2	6
125	New insight into the Pleistocene deposits of Monte delle Piche, Rome, and remarks on the biochronology of Hippopotamus (Mammalia, Hippopotamidae) and Stephanorhinus etruscus (Mammalia, Rhinocerotidae) in Italy. <i>Estudios Geologicos</i> , 2015 , 71, e026	0.3	9
124	MicroRNA prognostic signature in malignant pleural mesothelioma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 7562-7562	2.2	
123	The role of circulating free DNA (cfDNA) and circulating tumor cells (CTC) in advanced non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy (CHT).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e19090-e19090	2.2	
122	Role of microRNAs in malignant mesothelioma. <i>Cellular and Molecular Life Sciences</i> , 2014 , 71, 2865-78	10.3	30
121	Afatinib for the treatment of advanced non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 889-903	4	19
120	A peer-education based disaster medicine course to turn medical students into a useful resource. <i>International Journal of Disaster Risk Reduction</i> , 2014 , 8, 153-157	4.5	2
119	Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014 , 140, 1783-93	4.9	7
118	Valutazione economica in base allo studio NAVoTRIAL01 con riferimento al contesto sanitario italiano: Vinorelbine orale e Cisplatino o Pemetrexed e Cisplatino seguiti da mantenimento rispettivamente con Vinorelbine orale e Pemetrexed nel trattamento del Carcinoma Polmonare Non-Small-Cell Lung Cancer (NSCLC) in stadio avanzato. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014 , 140, 1783-93		2
117	Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study. <i>Clinical Lung Cancer</i> , 2014 , 15, 338-45.e1	4.9	6
116	Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy. <i>Expert Opinion on Biological Therapy</i> , 2014 , 14, 1007-17	5.4	7
115	Prognostic and predictive relevance of circulating tumor cells in patients with non-small-cell lung cancer. <i>Drug Discovery Today</i> , 2014 , 19, 1671-6	8.8	30
114	DISRUPT: a randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane-platinum regimen as first-line therapy for metastatic non-small cell lung cancer. <i>Lung Cancer</i> , 2014 , 85, 224-9	5.9	20

113	Ramucirumab: preclinical research and clinical development. <i>OncoTargets and Therapy</i> , 2014 , 7, 1997-2006	4	39
112	Efficacy of motesanib diphosphate in non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 1771-80	4	
111	Third- and further-line therapy in advanced non-small-cell lung cancer patients: an overview. <i>Future Oncology</i> , 2014 , 10, 2081-96	3.6	13
110	Clinical Applications of Circulating Tumor Cells in Lung Cancer Patients by CellSearch System. <i>Frontiers in Oncology</i> , 2014 , 4, 242	5.3	53
109	Oral vinorelbine in the treatment of non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 1585-99	4	18
108	Role of immunotherapy in the treatment of advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2014 , 10, 79-90	3.6	21
107	Dynamic behaviour of lactate values during mild hypothermia in patients with cardiac arrest. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2014 , 3, 176-82	4.3	3
106	Evaluation of antitumor activity using change in tumor size of the survivin antisense oligonucleotide LY2181308 in combination with docetaxel for second-line treatment of patients with non-small-cell lung cancer: a randomized open-label phase II study. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 1713-7	8.9	22
105	Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 733-7	8.9	24
104	Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2014 , 15, 713-21	21.7	131
103	Continuation of afatinib beyond progression: Results of a randomized, open-label, phase III trial of afatinib plus paclitaxel (P) versus investigator choice chemotherapy (CT) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) progressed on erlotinib/gefitinib (E/G) and afatinib (UX-Lung 5 (LL5)). <i>Journal of Clinical Oncology</i> , 2014 , 32, 8019-8019	2.2	16
102	Potential of crizotinib activity by fasting cycles in an ALK+ lung cancer model.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e13511-e13511	2.2	1
101	Serum mass-spectrometry test in first-line advanced NSCLC patients treated with standard chemotherapy regimens.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e19090-e19090	2.2	
100	Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. <i>British Journal of Cancer</i> , 2013 , 109, 552-8	8.7	75
99	Pemetrexed for the treatment of non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 1545-58	4	21
98	Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052). <i>European Journal of Cancer</i> , 2013 , 49, 2815-22	7.5	38
97	Glyceraldehyde-3-phosphate dehydrogenase gene over expression correlates with poor prognosis in non small cell lung cancer patients. <i>Molecular Cancer</i> , 2013 , 12, 97	42.1	26
96	Free drugs in clinical trials and their potential cost saving impact on the National Health Service: a retrospective cost analysis in Italy. <i>Lung Cancer</i> , 2013 , 81, 236-40	5.9	18

95	Easternmost Mediterranean evidence of the Zanclean flooding event and subsequent surface uplift: Adana Basin, southern Turkey. <i>Geological Society Special Publication</i> , 2013 , 372, 473-494	1.7	24
94	ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin. <i>British Journal of Cancer</i> , 2013 , 108, 1695-703	8.7	60
93	Pleural and peripheral lung lesions: comparison of US- and CT-guided biopsy. <i>Radiology</i> , 2013 , 266, 930-520.5	20.5	94
92	Afatinib in advanced non-small-cell lung cancer. <i>Lung Cancer Management</i> , 2013 , 2, 493-504	2.6	
91	A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC). <i>Annals of Oncology</i> , 2013 , 24, 2382-9	10.3	43
90	Mobile emergency, an emergency support system for hospitals in mobile devices: pilot study. <i>JMIR Research Protocols</i> , 2013 , 2, e19	2	3
89	A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 369-75	3.5	2
88	Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2012 , 61, 1463-72	7.4	95
87	Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2012 , 12, 939-48	5.4	18
86	A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer. <i>Lung Cancer</i> , 2012 , 76, 465-71	5.9	19
85	Management of non-small cell lung in cancer patients with stable disease. <i>Drugs</i> , 2012 , 72 Suppl 1, 20-7	12.1	4
84	Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer. <i>ClinicoEconomics and Outcomes Research</i> , 2012 , 4, 31-7	1.7	19
83	The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 1407-12	3.5	8
82	Orbitally forced paleoenvironmental and paleoclimate changes in the late postevaporitic Messinian of the central Mediterranean Basin. <i>Bulletin of the Geological Society of America</i> , 2012 , 124, 499-516	3.9	27
81	Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST). <i>British Journal of Cancer</i> , 2012 , 106, 658-65	8.7	14
80	Gender-related difference in ST-elevation myocardial infarction treated with primary angioplasty: a single-centre 6-year registry. <i>European Journal of Preventive Cardiology</i> , 2012 , 19, 233-40	3.9	38
79	Afatinib monotherapy in patients with metastatic squamous cell carcinoma of the lung progressing after erlotinib/gefitinib (E/G) and chemotherapy: Interim subset analysis from a phase III trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7558-7558	2.2	3
78	9112 POSTER AVAPERL1 (MO22089) Interim Safety of Maintenance (mtc) Bevacizumab (bev) + Pemetrexed (pern) in Patients (pts) With Advanced Non-squamous Non-small Cell Lung Cancer (nsNSCLC) After First-line (1L) Bev-cisplatin (cis)-pem Treatment (Tx). <i>European Journal of Cancer</i> , 2011 , 47, 8686	7.5	2

77	Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain. <i>Lung Cancer</i> , 2011 , 74, 529-34	5.9	25
76	A randomised phase II study of docetaxel/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group trial (ATOM 019). <i>European Journal of Cancer</i> , 2011 , 47, 1653-9	7.5	4
75	Phase II study of sunitinib in patients with non-small cell lung cancer and irradiated brain metastases. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1260-6	8.9	36
74	Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaATL (MO22097) trial. <i>Clinical Lung Cancer</i> , 2011 , 12, 407-11	4.9	38
73	Anti-cancer activity of 5-O-alkyl 1,4-imino-1,4-dideoxyribitols. <i>Bioorganic and Medicinal Chemistry</i> , 2011 , 19, 7720-7	3.4	13
72	Evaluation of CTL antigen 4 (CTLA-4) expression as prognostic factor in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2011 , 29, e21157-e21157	2.2	2
71	Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1835-42	2.2	379
70	Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens. <i>Oncologist</i> , 2010 , 15, 1102-12	5.7	56
69	Messinian Lago-Mare deposits near the Strait of Gibraltar (Malaga Basin, S Spain). <i>Palaeogeography, Palaeoclimatology, Palaeoecology</i> , 2010 , 285, 264-276	2.9	44
68	Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy. <i>Lung Cancer</i> , 2010 , 69 Suppl 1, S11-7	5.9	24
67	Prognostic stratification of stage IIIA pN2 non-small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary Group study (ATOM 014). <i>Journal of Thoracic Oncology</i> , 2010 , 5, 1354-60	8.9	23
66	Novel 2-[(benzylamino)methyl]pyrrolidine-3,4-diol derivatives as alpha-mannosidase inhibitors and with antitumor activities against hematological and solid malignancies. <i>Bioorganic and Medicinal Chemistry</i> , 2010 , 18, 3320-34	3.4	22
65	Synthesis of new oxathiazinane dioxides and their in vitro cancer cell growth inhibitory activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010 , 20, 5353-6	2.9	4
64	Phase II study of sunitinib in patients with non-small cell lung cancer (NSCLC) and irradiated brain metastases: Final efficacy and safety results.. <i>Journal of Clinical Oncology</i> , 2010 , 28, 7581-7581	2.2	2
63	Docetaxel (D) versus docetaxel/gemcitabine (D&G) in the treatment of older patients with advanced non-small cell lung cancer (NSCLC): An Alpe Adria Thoracic Oncology Multidisciplinary Group randomized phase II trial (ATOM 017).. <i>Journal of Clinical Oncology</i> , 2010 , 28, e18028-e18028	2.2	2
62	IL-12 can target human lung adenocarcinoma cells and normal bronchial epithelial cells surrounding tumor lesions. <i>PLoS ONE</i> , 2009 , 4, e6119	3.7	30
61	Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach. <i>Oncologist</i> , 2009 , 14, 497-510	5.7	49
60	IL-8 induces exocytosis of arginase 1 by neutrophil polymorphonuclears in nonsmall cell lung cancer. <i>International Journal of Cancer</i> , 2009 , 125, 887-93	7.5	117

59	An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy. <i>Lung Cancer</i> , 2009 , 64, 199-206	5.9	19
58	Administration of sunitinib to patients with non-small cell lung cancer and irradiated brain metastases: A phase II trial. <i>Journal of Clinical Oncology</i> , 2009 , 27, 8077-8077	2.2	2
57	Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. <i>British Journal of Cancer</i> , 2008 , 99, 51-6	8.7	93
56	Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer. <i>BMC Cancer</i> , 2008 , 8, 216	4.8	22
55	Earliest Zanclean age for the Colombacci and uppermost Di Tetto formations of the latest Messinian northern Apennines: New palaeoenvironmental data from the Maccarone section (Marche Province, Italy) by Popescu et al. (2007) <i>Geobios</i> 40 (359-373). <i>Geobios</i> , 2008 , 41, 669-675	1.5	14
54	Late Messinian lago-mare ostracod palaeoecology: A correspondence analysis approach. <i>Palaeogeography, Palaeoclimatology, Palaeoecology</i> , 2008 , 264, 288-295	2.9	26
53	Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer. <i>Oncologist</i> , 2008 , 13 Suppl 1, 14-20	5.7	67
52	Chemotherapy plus bevacizumab in the first-line treatment of non-small cell lung cancer: benefits, risks and limitations. <i>Memo - Magazine of European Medical Oncology</i> , 2008 , 1, 13-16	0.3	0
51	Arginase 2 is expressed by human lung cancer, but it neither induces immune suppression, nor affects disease progression. <i>International Journal of Cancer</i> , 2008 , 123, 1108-16	7.5	33
50	Identifying an optimum treatment strategy for patients with advanced non-small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2008 , 67, 16-26	7	14
49	Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2008 , 68, 183-96	7	26
48	Should 3-weekly docetaxel (3WD) remain the standard for second-line therapy of advanced non-small-cell lung cancer (A-NSCLC)? Meta-analysis of 7 randomized clinical trials (RCTs) with 3WD comparator arms. <i>Journal of Clinical Oncology</i> , 2008 , 26, 8087-8087	2.2	2
47	Predictive and prognostic significance of neuron-specific enolase (NSE) in non-small cell lung cancer. <i>Anticancer Research</i> , 2008 , 28, 507-13	2.3	17
46	PCN36 ECONOMIC EVALUATION OF ERLOTINIB, DOCETAXEL AND PEMETREXEDAS SECOND LINE TREATMENT IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC). A COST-MINIMIZATION IN ITALIAN HOSPITALS. <i>Value in Health</i> , 2007 , 10, A333	3.3	3
45	Valutazione economica di erlotinib, docetaxel e pemetrexed nel trattamento di seconda linea del carcinoma polmonare non a piccole cellule. <i>Pharmacoeconomics Italian Research Articles</i> , 2007 , 9, 113-124		7
44	Paratethyan Ostracod immigrants in Italy during the Late Miocene. <i>Geobios</i> , 2007 , 40, 325-337	1.5	40
43	Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 6518-26	12.9	20
42	Bevacizumab and non-small-cell lung cancer: starving the enemy to survive. <i>Expert Opinion on Biological Therapy</i> , 2007 , 7, 1107-19	5.4	4

41	Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature. <i>Oncologist</i> , 2007 , 12, 451-64	5.7	54
40	Low-dose computed tomography screening for lung cancer and pleural mesothelioma in an asbestos-exposed population: baseline results of a prospective, nonrandomized feasibility trial--an Alpe-adria Thoracic Oncology Multidisciplinary Group Study (ATOM 002). <i>Oncologist</i> , 2007 , 12, 1215-24	5.7	57
39	Informal caregiving burden in advanced non-small cell lung cancer: the HABIT study. <i>Journal of Thoracic Oncology</i> , 2007 , 2, 475-80	8.9	19
38	Pretreatment and prospective assessment of endometrium in menopausal women taking tamoxifen for breast cancer. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2007 , 132, 101-6	2.4	16
37	Gefitinib (G) treatment outcome after progression on erlotinib (E) in patients with advanced non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2007 , 25, 18138-18138	2.2	2
36	Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer. <i>Cancer</i> , 2006 , 107, 2842-9	6.4	76
35	Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: a phase II trial from an Italian cooperative group. <i>Acta Oncologica</i> , 2006 , 45, 168-74	3.2	15
34	Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 1443-8	2.2	224
33	Maintenance chemotherapy in non-small cell lung cancer. <i>Annals of Oncology</i> , 2006 , 17 Suppl 2, ii67-70	10.3	12
32	O2 Pemetrexed in combination with carboplatin in elderly patients with malignant pleural mesothelioma (MPM). <i>Critical Reviews in Oncology/Hematology</i> , 2006 , 60, S18	7	
31	Phase II study of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 007). <i>Lung Cancer</i> , 2006 , 52, 89-92	5.9	10
30	Adjuvant chemotherapy for non-small cell lung cancer: ready for clinical practice?. <i>European Journal of Cancer</i> , 2006 , 42, 8-16	7.5	28
29	Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC). <i>Critical Reviews in Oncology/Hematology</i> , 2006 , 58, 221-30	7	15
28	In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines. <i>Oncology Research</i> , 2005 , 15, 39-48	4.8	42
27	To treat or not to treat advanced non-small-cell lung cancer patients with impaired performance status?. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7231-2; author reply 7232	2.2	3
26	A phase II study of pemetrexed and carboplatin as front-line chemotherapy in patients with malignant pleural mesothelioma (MPM). <i>Journal of Clinical Oncology</i> , 2005 , 23, 7172-7172	2.2	4
25	Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil. <i>British Journal of Cancer</i> , 2004 , 91, 1428-33	8.7	1
24	Outpatient hysteroscopic polypectomy in 237 patients: feasibility of a one-stop "see-and-treat" procedure. <i>Journal of Minimally Invasive Gynecology</i> , 2004 , 11, 500-4		32

23	Sequential chemotherapy with paclitaxel plus cisplatin, followed by vinorelbine, followed by gemcitabine in advanced non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 001). <i>Lung Cancer</i> , 2004 , 46, 99-106	5.9	9
22	Information given to cancer patients on diagnosis, prognosis and treatment: the clinical oncologist's perspective. <i>European Journal of Cancer</i> , 2004 , 40, 1850-4	7.5	8
21	Tumor measurements on computed tomographic images of non-small cell lung cancer were similar among cancer professionals from different specialties. <i>Journal of Clinical Epidemiology</i> , 2004 , 57, 804-8	5.7	12
20	Geography of clinical cancer research publications from 1995 to 1999. <i>European Journal of Cancer</i> , 2003 , 39, 106-11	7.5	46
19	The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992). <i>European Journal of Cancer</i> , 2003 , 39, 353-7	7.5	59
18	Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers. <i>European Journal of Cancer</i> , 2003 , 39, 1242-50	7.5	66
17	Phase II study of neoadjuvant chemotherapy in patients with surgically-proven, unresectable stage III non-small cell lung cancer. <i>Anticancer Research</i> , 2002 , 22, 3519-24	2.3	5
16	The role of systemic chemotherapy in the treatment of brain metastases from small-cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2001 , 37, 61-7	7	45
15	5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer. <i>British Journal of Cancer</i> , 2001 , 84, 1023-8	8.7	6
14	Interaction between novel anticancer agents and radiation in non-small cell lung cancer cell lines. <i>Lung Cancer</i> , 2001 , 33, 27-39	5.9	21
13	Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a randomized study. GISCAD, IOR and collaborating centers. <i>Annals of Oncology</i> , 2000 , 11, 1413-20	10.3	13
12	Managing patients with lung cancer 2000 , 320, 379-379		3
11	. <i>Annals of Oncology</i> , 2000 , 11, 101-110	10.3	3
10	Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity. <i>International Journal of Oncology</i> , 1999 , 15, 787-92	1	3
9	The combination of etoposide and cisplatin in non-small-cell lung cancer (NSCLC). <i>Annals of Oncology</i> , 1999 , 10 Suppl 5, S13-7	10.3	13
8	New perspectives for the pharmacological and biological therapy of small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 1999 , 31, 135-45	7	3
7	Induction chemotherapy followed by concurrent standard radiotherapy and daily low-dose cisplatin in locally advanced non-small-cell lung cancer. <i>British Journal of Cancer</i> , 1999 , 81, 310-5	8.7	20
6	Management of malignant pleural effusions. <i>Drugs</i> , 1998 , 55, 47-58	12.1	26

5	Analysis of K-ras, p53, bcl-2 and Rb expression in non-small cell lung cancer cell lines. <i>International Journal of Oncology</i> , 1997 , 11, 1203-8	1	1
4	Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients. <i>Cytotechnology</i> , 1996 , 19, 215-9	2.2	4
3	Penetration of cefonicid into serum, salpinges, cervix and vaginal tissue. <i>Journal of Chemotherapy</i> , 1991 , 3, 28-9	2.3	4
2	Introduction of the beta isozyme of protein kinase C accelerates induced differentiation of murine erythroleukemia cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990 , 87, 4417-20	11.5	45
1	Clinicopathologic correlates of pembrolizumab efficacy in patients with advanced NSCLC and a PD-L1 expression of $\geq 50\%$		1